CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
For the period ended Jun 27, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 27, 2026 · Filed Aug 5, 2026
CRL$345.80-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except per share amounts)
| June 27, 2026 | December 27, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $192,025 | $213,770 |
| Trade receivables and contract assets, net of allowances for credit losses of $8,715 and $10,463, respectively | 711,755 | 708,856 |
| Inventories | 346,260 | 299,103 |
| Prepaid assets | 100,409 | 96,108 |
| Other current assets | 178,657 | 129,212 |
| Total current assets | 1,529,106 | 1,447,049 |
| Property, plant and equipment, net | 1,494,914 | 1,655,219 |
| Venture capital and strategic equity investments | 206,470 | 206,972 |
| Operating lease right-of-use assets, net | 330,247 | 361,415 |
| Goodwill | 3,076,851 | 2,764,253 |
| Intangible assets, net | 253,174 | 339,995 |
| Deferred tax assets | 53,827 | 67,334 |
| Other assets | 587,556 | 293,185 |
| Total assets | $7,532,145 | $7,135,422 |
| Liabilities, Redeemable Noncontrolling Interests and Equity | ||
| Current liabilities: | ||
| Accounts payable | $140,983 | $148,800 |
| Accrued compensation | 187,835 | 268,854 |
| Deferred revenue | 203,035 | 210,418 |
| Accrued liabilities | 380,101 | 270,085 |
| Other current liabilities | 222,792 | 222,158 |
| Total current liabilities | 1,134,746 | 1,120,315 |
| Long-term debt, net and finance leases | 2,619,985 | 2,136,360 |
| Operating lease right-of-use liabilities | 407,708 | 434,048 |
| Deferred tax liabilities | 78,668 | 95,203 |
| Other long-term liabilities | 402,511 | 138,302 |
| Total liabilities | 4,643,618 | 3,924,228 |
| Commitments and contingencies (Notes 2, 12, 14, and 16) | ||
| Redeemable noncontrolling interests | 42,537 | 41,263 |
| Equity: | ||
| Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.01 par value; 120,000 shares authorized; 49,550 shares issued and 47,728 shares outstanding as of June 27, 2026, and 49,217 shares issued and outstanding as of December 27, 2025 | 496 | 492 |
| Additional paid-in capital | 1,986,023 | 1,947,301 |
| Retained earnings | 1,372,295 | 1,388,620 |
| Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively | (323,189) | — |
| Accumulated other comprehensive loss | (195,989) | (171,783) |
| Total Charles River Laboratories International, Inc. equity | 2,839,636 | 3,164,630 |
| Nonredeemable noncontrolling interest | 6,354 | 5,301 |
| Total equity | 2,845,990 | 3,169,931 |
| Total liabilities, redeemable noncontrolling interests and equity | $7,532,145 | $7,135,422 |
| See Notes to Unaudited Condensed Consolidated Financial Statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.